Black Diamond Therapeutics Inc (BDTX) - News Archive

SURESNES, France and CAMBRIDGE, Mass. March 19, 2025 Servier, an independent global pharmaceutical group guided by a non-profit foundation, and Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology...

Advancing Oncogenic Therapeutics: Black Diamond Therapeutics Reports Promising Financial and Corporate DevelopmentsIn an era where precision medicine is not merely an ambition but an urgent necessity, Black Diamond Ther...

In a pivotal move in the oncology sector, Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) recently announced compelling results in their ongoing clinical trials for BDTX-1535, a new hope in the treatment of recurrent EG...

Black Diamond Therapeutics Announces Initial Phase 2 BDTX-1535 Results in Recurrent EGFRm NSCLC Patients: A Promising Step Forward Black Diamond Therapeutics, a leading precision oncology medicine company, has announced...

A Promising Step Forward in Glioblastoma Treatment: BDTX-1535 Shows Encouraging Clinical Data Recurrent glioblastoma multiforme (GBM), a highly aggressive malignant brain tumor, remains one of the most challenging cance...

Black Diamond Therapeutics, Inc., a prominent clinical-stage oncology company committed to revolutionizing treatment paradigms, has recently revealed that it will play a key part at the forthcoming 2024 American Society...

The company presented robust data underlining that 20-30% of all patients diagnosed with EGFR mutation NSCLC, which is the most common type of lung cancer, are confronting non-classical mutations. This current scientifi...

Black Diamond Therapeutics, a leading precision oncology medicine firm, has applied disruptive technology to discover a new class of targeted therapies, the allosteric inhibitors. The company recently unveiled an ambiti...